Internal Medicine · New Haven, CT
NPI
1962658344
Since 2008
Specialty
Internal Medicine
Code 390200000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
20 York St, T-209
New Haven, CT, 06510
Phone (203) 688-2259
Groups this clinician bills Medicare through
Medicare paid, 2024
$88K
4,925 services
Medicare patients, 2024
19
Average age 68
Drug cost, 2024
$6.7M
2,196 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Warren Lok prescribed most often to Medicare patients was Abiraterone Acetate, with 266 prescriptions and refills. In total Warren Lok wrote 2,196 Medicare prescriptions that cost $6.7M.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-12-10.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Abiraterone Acetate Generic | 266 | 324 | 44 | $42K |
| Letrozole Generic | 169 | 505 | 54 | $3,403 |
| Prednisone Generic | 168 | 424 | 58 | $1,584 |
| Lenalidomide Generic | 110 | 110 | 16 | $1.4M |
| Dexamethasone Generic | 102 | 136 | 40 | $1,749 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 86 | 86 | 20 | $1,472 |
| Exemestane Generic | 66 | 198 | 22 | $5,487 |
| Xtandi Enzalutamide | 64 | 64 | Under 11 | $772K |
| Hydroxyurea Generic | 56 | 169 | 19 | $2,181 |
| Brukinsa Zanubrutinib | 54 | 54 | Under 11 | $642K |
| Levothyroxine Sodium Generic | 50 | 146 | 11 | $996 |
| Gabapentin Generic | 45 | 81 | 13 | $722 |
| Lenvima Lenvatinib Mesylate | 42 | 42 | Under 11 | $869K |
| Nubeqa Darolutamide | 41 | 41 | Under 11 | $459K |
| Tamoxifen Citrate Generic | 40 | 109 | 14 | $1,058 |
Brand drugs: - claims; generic drugs: 1,700 claims; opioid claims: 173.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Warren Lok were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.